Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of 131I on the in vivo management of differentiated thyroid cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of 131I on the in vivo management of differentiated thyroid cancer

Published:2012-12 Issue:23-24 Volume:91 Page:1236-1241
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Meng Zhaowei,Lou Shanshan,Tan Jian,Xu Ke,Jia Qiang,Zheng Wei,Wang Shen

Funder

China National Natural Science Foundation

Key Project of Tianjin Science and Technology Committee Foundation

Tianjin Medical University Scientific Research

Tianjin Medical University New Century Excellent Talent Program

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference57 articles.

1. Survival analysis of 19 patients with toxic thyroid carcinoma;Als;J Clin Endocrinol Metab,2002

2. Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves' disease;Basaria;J Endocrinol Invest,2002

3. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression;Basseres;Oncogene,2006

4. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls;Baud;Nat Rev Drug Discov,2009

5. NF-kappaB addiction and its role in cancer: ‘one size does not fit all’;Chaturvedi;Oncogene,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics;Cancer Letters;2020-01

2. Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS;Redox Biology;2018-06

3. Association of NF-κB polymorphisms with clinical outcome of non-medullary thyroid carcinoma;Endocrine-Related Cancer;2017-07

4. Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer;PLOS ONE;2015-08-11

5. Synergistic Effects of Combining Anti-Midkine and Hepatocyte Growth Factor Therapies Against Diabetic Nephropathy in Rats;The American Journal of the Medical Sciences;2015-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3